ALS patients get extended access to experimental treatment in Follow-Up study
NCT ID NCT05299658
Summary
This study offers extended treatment with CNM-Au8 to patients with early ALS who completed the initial trial. The goal is to continue assessing whether this experimental treatment can slow disease progression while monitoring safety. Participants receive the active treatment for up to 48 weeks or longer while researchers track side effects and muscle function changes.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Concord Hospital
Concord, New South Wales, 2139, Australia
-
Neuroscience Research Australia
Randwick, New South Wales, 2031, Australia
Conditions
Explore the condition pages connected to this study.